| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Şevin Hun Şenol, Gamze Gürcan, Aygün Ertuğrul, Sevilay Karahan, A Elif Anıl Yağcıoğl. [Augmentation of Clozapine Due to Inadequate Treatment Response in Schizophrenia: Comparison of Patients with Augmented and Non-augmented Treatments]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 1. 2021-10-28. PMID:34181738. |
this study aims to investigate clozapine augmentation methods utilized in schizophrenia and compare the sociodemographic characteristics, clinical features and remission states of patients whose treatments are augmented and not. |
2021-10-28 |
2023-08-13 |
Not clear |
| Özlem Devrim Balaban, Zozan Parsanoğlu, Özge Arıkan, Özlem Gü. [Should C-Reactive Protein and Troponin Be Monitored for Early Diagnosis of Clozapine Induced Myocarditis? An Assessment Within the Framework of Two Cases]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 1. 2021-10-28. PMID:34181745. |
clozapine is an important treatment option in patients with treatmentresistant schizophrenia and bipolar disorder. |
2021-10-28 |
2023-08-13 |
Not clear |
| Gamze Gürcan, Şevin Hun Şenol, A Elif Anıl Yağcıoğlu, Sevilay Karahan, Aygün Ertuğru. Common Side Effects and Metabolic Syndrome due to Clozapine: Relationship with the Clinical Variables and Disability. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 2. 2021-10-28. PMID:34392505. |
in this study, we aimed to assess the common side effects and the prevalence of metabolic syndrome in schizophrenia patients treated with clozapine, and to study their relationship with clinical variables and disability. |
2021-10-28 |
2023-08-13 |
Not clear |
| Burcu Kök Kendirlioğlu, Aytül Gürsu Harir. Could Weight Loss During Clozapine Therapy be an Indicator of Poor Response?: A Case Report. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 2. 2021-10-28. PMID:34392510. |
even though effectiveness of clozapine on treatment resistant schizophrenia has been repeatedly demonstrated, it is also associated with many adverse effects including weight gain. |
2021-10-28 |
2023-08-13 |
Not clear |
| Burcu Kök Kendirlioğlu, Aytül Gürsu Harir. Could Weight Loss During Clozapine Therapy be an Indicator of Poor Response?: A Case Report. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 2. 2021-10-28. PMID:34392510. |
he was diagnosed with treatment-resistant schizophrenia and started on clozapine with dose titration to 500 mg/day over 3 months. |
2021-10-28 |
2023-08-13 |
Not clear |
| Burcu Kök Kendirlioğlu, Aytül Gürsu Harir. Could Weight Loss During Clozapine Therapy be an Indicator of Poor Response?: A Case Report. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 32. issue 2. 2021-10-28. PMID:34392510. |
there is a need for more case-control and preclinical studies to explain the mechanisms underlying weight loss and weak response to clozapine therapy in schizophrenia. |
2021-10-28 |
2023-08-13 |
Not clear |
| Maximilian Huhn, Claudia Leucht, Philipp Rothe, Markus Dold, Stephan Heres, Susanne Bornschein, Thomas Schneider-Axmann, Alkomiet Hasan, Stefan Leuch. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. European archives of psychiatry and clinical neuroscience. vol 271. issue 2. 2021-10-27. PMID:32062728. |
we included chronic, adult patients with schizophrenia or schizoaffective disorder, who were treated with any antipsychotic drug except clozapine, who had not been hospitalized in the last 3 years and who were in symptomatic remission at baseline. |
2021-10-27 |
2023-08-13 |
Not clear |
| Vladimir Sazhin, Pushkal Pushka. Predictors of laxative use in inpatients with schizophrenia on clozapine. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. 2021-10-27. PMID:34702103. |
predictors of laxative use in inpatients with schizophrenia on clozapine. |
2021-10-27 |
2023-08-13 |
Not clear |
| Jan M Griffin, Edgar Woznica, Nisha A Gilotra, Frederick C Nucifor. Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge. Journal of clinical psychopharmacology. vol 41. issue 2. 2021-10-26. PMID:33587399. |
clozapine is the only medication with food and drug administration approval for treatment-resistant schizophrenia. |
2021-10-26 |
2023-08-13 |
Not clear |
| Alberto Forte, Maurizio Pompili, Benedetta Imbastaro, Gabriele Pasquale De Luca, Martina Mastrangelo, Benedetta Montalbani, Ross J Baldessarin. Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. Journal of psychopharmacology (Oxford, England). vol 35. issue 9. 2021-10-26. PMID:34291676. |
effects on suicidal risk: comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. |
2021-10-26 |
2023-08-13 |
Not clear |
| Alberto Forte, Maurizio Pompili, Benedetta Imbastaro, Gabriele Pasquale De Luca, Martina Mastrangelo, Benedetta Montalbani, Ross J Baldessarin. Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. Journal of psychopharmacology (Oxford, England). vol 35. issue 9. 2021-10-26. PMID:34291676. |
clozapine is the only treatment with regulatory-recognition of lowering suicidal risk, at least in schizophrenia patients. |
2021-10-26 |
2023-08-13 |
Not clear |
| Amol N Patil, Kripa Shanker Kasudhan, M Naveen, Gurpreet Kaur Batra, Subho Chakrabarti, Ajit Avasthi, Sandeep Grove. Precise pharmacogenetic pharmacometabolomic (PPP) guided clozapine therapy in treatment resistant schizophrenia: Insights from one ethnicity experiment. Schizophrenia research. vol 237. 2021-10-26. PMID:34481201. |
precise pharmacogenetic pharmacometabolomic (ppp) guided clozapine therapy in treatment resistant schizophrenia: insights from one ethnicity experiment. |
2021-10-26 |
2023-08-13 |
Not clear |
| Elias Wagner, John M Kane, Christoph U Correll, Oliver Howes, Dan Siskind, William G Honer, Jimmy Lee, Peter Falkai, Thomas Schneider-Axmann, Alkomiet Hasa. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia bulletin. vol 46. issue 6. 2021-10-25. PMID:32421188. |
clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the treatment response and resistance in psychosis (trrip) working group. |
2021-10-25 |
2023-08-13 |
Not clear |
| Elias Wagner, John M Kane, Christoph U Correll, Oliver Howes, Dan Siskind, William G Honer, Jimmy Lee, Peter Falkai, Thomas Schneider-Axmann, Alkomiet Hasa. Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia bulletin. vol 46. issue 6. 2021-10-25. PMID:32421188. |
evidence for the management of inadequate clinical response to clozapine in treatment-resistant schizophrenia is sparse. |
2021-10-25 |
2023-08-13 |
Not clear |
| R J Flanagan, J Lally, S Gee, R Lyon, S Every-Palme. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. British medical bulletin. vol 135. issue 1. 2021-10-25. PMID:32885238. |
clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. |
2021-10-25 |
2023-08-13 |
Not clear |
| R J Flanagan, J Lally, S Gee, R Lyon, S Every-Palme. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. British medical bulletin. vol 135. issue 1. 2021-10-25. PMID:32885238. |
clozapine remains the only medication licensed for treating refractory schizophrenia. |
2021-10-25 |
2023-08-13 |
Not clear |
| Leslie Citrome, Jan Volavk. Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard review of psychiatry. vol 29. issue 1. 2021-10-25. PMID:33417374. |
specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine. |
2021-10-25 |
2023-08-13 |
Not clear |
| Deanna L Kelly, Olga Y Ponomareva, Marie Mackowick, Matthew Glassman, Jaeboon Park, Myriam Navarro-De La Vega, Heidi J Wehring, Gopal Vya. Feasibility and patient-reported satisfaction using a novel point-of-care fingerstick method for monitoring absolute neutrophil count for clozapine. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 33. issue 2. 2021-10-25. PMID:33878286. |
clozapine is an effective antipsychotic for treatment-resistant schizophrenia. |
2021-10-25 |
2023-08-13 |
Not clear |
| Zsuzsanna Belteczki, Julia Ujvari, Peter Dom. Clozapine Withdrawal-Induced Malignant Catatonia or Neuroleptic Malignant Syndrome: A Case Report and a Brief Review of the Literature. Clinical neuropharmacology. vol 44. issue 4. 2021-10-25. PMID:34132673. |
furthermore, we present the case of a 29-year-old male patient with schizophrenia in whom a malignant catatonic episode/neuroleptic malignant syndrome (with negativism, stupor, mutism, autonomic signs [eg, fever, hyperhidrosis], and elevated creatine kinase levels) began 5 days after the patient decided arbitrarily to cease his clozapine treatment. |
2021-10-25 |
2023-08-13 |
Not clear |
| Amir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, Dan Joyce, Derek K Tracy, Fiona Gaughran, James H MacCabe, Sukhwinder S Shergil. Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. Therapeutic advances in psychopharmacology. vol 11. 2021-10-23. PMID:34676067. |
outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. |
2021-10-23 |
2023-08-13 |
Not clear |